Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
ADC Therapeutics announces interim results from Phase 2 clinical trial of Cami » 09:59
06/22/21
06/22
09:59
06/22/21
09:59
ADCT

ADC Therapeutics

$25.13 /

-0.03 (-0.12%)

ADC Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ADCT ADC Therapeutics
$25.13 /

-0.03 (-0.12%)

ADCT ADC Therapeutics
$25.13 /

-0.03 (-0.12%)

06/15/21 Cantor Fitzgerald
ADC Therapeutics initiated with an Overweight at Cantor Fitzgerald
06/15/21 Cantor Fitzgerald
ADC Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
ADCT ADC Therapeutics
$25.13 /

-0.03 (-0.12%)

  • 24
    Sep
Friday
Hot Stocks
ADC Therapeutics presents data on four Zynlonta clinical trials » 07:23
06/18/21
06/18
07:23
06/18/21
07:23
ADCT

ADC Therapeutics

$22.95 /

-0.18 (-0.78%)

ADC Therapeutics…

ADC Therapeutics announced that posters on four Zynlonta clinical trials were presented at the 16th Annual International Conference on Malignant Lymphoma, or ICML. In LOTIS-2, a single-arm, open-label, 145-patient Phase 2 clinical trial in patients with relapsed or refractory DLBCL who had failed two established therapies, Zynlonta demonstrated continued substantial antitumor activity and an acceptable safety profile. Updated results were presented in a poster. As of the data cut-off date of March 1, all patients had completed treatment. Overall response rate, or ORR, was 48.3% and complete response rate, or CRR, was 24.8%. Median duration of response, or mDoR, of 13.4 months for the 70 responders. Median duration of response not reached for patients with a complete response. Median overall survival was 9.5 months. No new safety concerns were identified during the study and no increase in toxicity was observed in patients aged 65 years compared with patients less than 65 years. The most common grade 3 treatment-emergent adverse events. or TEAEs, were neutropenia, thrombocytopenia, increased gamma-glutamyltransferase and anemia. LOTIS-3, a Phase 1/2, two-part, open-label, single-arm clinical trial, is evaluating Zynlonta in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, or mantle cell lymphoma, or MCL. Updated Phase 1 results were presented in a poster. As of the data cut-off date of March 1, 30 patients with DLBCL and seven patients with MCL were included in the study. ORR in all patients was 62.2% and CRR was 35.1%. In non-GCB DLBCL patients, ORR was 66.7%. In GCB DLBCL patients, ORR was 16.7%. In MCL patients, ORR was 85.7%. Zynlonta in combination with ibrutinib had manageable toxicity, with the most common grade 3 TEAEs in 5% of patients being anemia, neutropenia, thrombocytopenia and fatigue. Pharmacokinetic profiles demonstrated sustained exposure and modest accumulation by Cycle 2

ShowHide Related Items >><<
ADCT ADC Therapeutics
$22.95 /

-0.18 (-0.78%)

ADCT ADC Therapeutics
$22.95 /

-0.18 (-0.78%)

06/15/21 Cantor Fitzgerald
ADC Therapeutics initiated with an Overweight at Cantor Fitzgerald
06/15/21 Cantor Fitzgerald
ADC Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
ADCT ADC Therapeutics
$22.95 /

-0.18 (-0.78%)

  • 24
    Sep
Over a week ago
Initiation
ADC Therapeutics initiated with an Overweight at Cantor Fitzgerald » 06:58
06/15/21
06/15
06:58
06/15/21
06:58
ADCT

ADC Therapeutics

$23.17 /

+1.015 (+4.58%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Brian Cheng initiated coverage of ADC Therapeutics with an Overweight rating and $46 price target. Cheng believes the current share price represents an attractive entry point based on strong underlying fundamentals and thinks the company's extensive pipeline portfolio is largely underappreciated as the floor of its valuation is well-supported by the growing revenue stream from Zynlonta sales, the analyst tells investors in a research note.

ShowHide Related Items >><<
ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

06/15/21 Cantor Fitzgerald
ADC Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

  • 24
    Sep
Initiation
ADC Therapeutics initiated with an Overweight at Cantor Fitzgerald » 06:53
06/15/21
06/15
06:53
06/15/21
06:53
ADCT

ADC Therapeutics

$23.17 /

+1.015 (+4.58%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Brian Cheng initiated coverage of ADC Therapeutics with an Overweight rating and $46 price target.

ShowHide Related Items >><<
ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
12/02/20 Stifel
ADC Therapeutics initiated with a Hold at Stifel
ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

  • 24
    Sep
Syndicate
ADC Therapeutics files $200M mixed securities shelf  16:30
06/04/21
06/04
16:30
06/04/21
16:30
ADCT

ADC Therapeutics

$22.03 /

-0.32 (-1.43%)

 
ShowHide Related Items >><<
ADCT ADC Therapeutics
$22.03 /

-0.32 (-1.43%)

ADCT ADC Therapeutics
$22.03 /

-0.32 (-1.43%)

05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
12/02/20 Stifel
ADC Therapeutics initiated with a Hold at Stifel
ADCT ADC Therapeutics
$22.03 /

-0.32 (-1.43%)

  • 24
    Sep
Hot Stocks
ADC Therapeutics announces updated clinical data from Phase 2 LOTIS-2 trial » 13:55
06/04/21
06/04
13:55
06/04/21
13:55
ADCT

ADC Therapeutics

$21.67 /

-0.68 (-3.04%)

ADC Therapeutics…

ADC Therapeutics announced updated clinical data from the Zylonta Phase 2 LOTIS-2 trial in patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, were presented at the 2021 American Society of Clinical Oncology, or ASCO, Annual Meeting, which is being held virtually June 4-8. Key data at the March 1, 2021 data cut include: Overall response rate, or ORR, was 48.3% and complete response rate, or CRR, was 24.8%; Median duration of response, or mDoR, of 13.4 months for the 70 responders; Median duration of response not reached for patients with a complete response. "The maturing duration of response from the ZYNLONTA Phase 2 trial reported at ASCO reflects the strong data set that served as the basis of the accelerated FDA approval in April. We are especially encouraged to see this positive trend continue to strengthen in a heavily pre-treated patient population, including patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65," said Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer of ADC Therapeutics.

ShowHide Related Items >><<
ADCT ADC Therapeutics
$21.67 /

-0.68 (-3.04%)

ADCT ADC Therapeutics
$21.67 /

-0.68 (-3.04%)

05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
12/02/20 Stifel
ADC Therapeutics initiated with a Hold at Stifel
ADCT ADC Therapeutics
$21.67 /

-0.68 (-3.04%)

  • 24
    Sep
Syndicate
ADC Therapeutics files to sell 5.56M shares of common stock for holders  17:04
06/01/21
06/01
17:04
06/01/21
17:04
ADCT

ADC Therapeutics

$22.15 /

+0.45 (+2.07%)

 
ShowHide Related Items >><<
ADCT ADC Therapeutics
$22.15 /

+0.45 (+2.07%)

ADCT ADC Therapeutics
$22.15 /

+0.45 (+2.07%)

05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
12/02/20 Stifel
ADC Therapeutics initiated with a Hold at Stifel
ADCT ADC Therapeutics
$22.15 /

+0.45 (+2.07%)

  • 24
    Sep
Hot Stocks
ADC Therapeutics announces results from camidanlumab tesirine study published » 07:30
05/26/21
05/26
07:30
05/26/21
07:30
ADCT

ADC Therapeutics

$20.63 /

-0.28 (-1.34%)

ADC Therapeutics…

ADC Therapeutics announced that results of the Phase 1 clinical trial of camidanlumab tesirine, or Cami, an anti-CD25 ADC, in patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas have been published online in The Lancet Haematology. The multicenter, open-label, single-arm, dose escalation and dose expansion Phase 1 clinical trial enrolled 133 adult patients, 77 with classical Hodgkin lymphoma and 56 with non-Hodgkin lymphoma. Enrolled patients were required to have pathologically confirmed relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma and no therapies with established clinical benefit for their disease stage available to them. In the total patient population, the overall response rate, or ORR, was 58%, with 38 of 130 patients reported to have a complete response. In heavily pretreated patients with Hodgkin lymphoma, across all doses, the ORR was 71%, with 32 of 77 patients reported to have a complete response. In Hodgkin lymphoma patients who received 45 microgram/kg, the ORR was 86%, with 18 of 37 patients reported to have a complete response. In Hodgkin lymphoma patients who received 30 microgram/kg, the ORR was 55%, with seven of 20 patients reported to have a complete response. In patients with non-Hodgkin lymphoma, the ORR was 38%, with five of 53 patients reported to have a complete response. The overall median duration of response was 6.6 months for all patients with Hodgkin lymphoma and 7.2 months for Hodgkin lymphoma patients who received 45 microgram/kg. Cami demonstrated an acceptable safety profile. The most commonly observed adverse events included elevated liver enzymes, rash, fatigue, oedema or effusion, and nausea. Based on the data from this Phase 1 clinical trial, a Phase 2 trial to further evaluate the safety and efficacy of Cami in patients with relapsed or refractory Hodgkin lymphoma is ongoing. Interim data from the pivotal Phase 2 trial presented at the 2020 American Society of Hematology meeting demonstrated encouraging antitumor activity as a single agent with an ORR of 83%, a complete response rate of 38% and no new safety signals. These data highlight the potential for Cami to address an unmet need in heavily pretreated patients.

ShowHide Related Items >><<
ADCT ADC Therapeutics
$20.63 /

-0.28 (-1.34%)

ADCT ADC Therapeutics
$20.63 /

-0.28 (-1.34%)

05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
12/02/20 Stifel
ADC Therapeutics initiated with a Hold at Stifel
ADCT ADC Therapeutics
$20.63 /

-0.28 (-1.34%)

  • 24
    Sep
Hot Stocks
Avid Bioservices to be commercial manufacturer for ADC Therapeutics' ZYNLONTA » 08:20
05/25/21
05/25
08:20
05/25/21
08:20
CDMO

Avid Bioservices

$20.17 /

+0.1 (+0.50%)

, ADCT

ADC Therapeutics

$20.91 /

+0.06 (+0.29%)

Avid Bioservices (CDMO)…

Avid Bioservices (CDMO) announced that it will serve as the commercial manufacturer for the humanized monoclonal antibody portion of ZYNLONTA, a recently approved cancer treatment developed by ADC Therapeutics SA (ADCT). Avid has provided clinical manufacturing services to ADC Therapeutics to support development of the product since 2017 and will now expand its manufacturing relationship with ADC Therapeutics to include commercial manufacturing activities for ZYNLONTA. ZYNLONTA is an antibody drug conjugate composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine dimer cytotoxin. In April 2021, ADC Therapeutics received Food and Drug Administration approval for ZYNLONTA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. As part of the ZYNLONTA approval process, Avid hosted the FDA earlier this year for the Pre-License Inspection, which was completed with no 483 observations.

ShowHide Related Items >><<
CDMO Avid Bioservices
$20.17 /

+0.1 (+0.50%)

ADCT ADC Therapeutics
$20.91 /

+0.06 (+0.29%)

CDMO Avid Bioservices
$20.17 /

+0.1 (+0.50%)

03/29/21 RBC Capital
Humanigen lenzilumab update 'an incremental positive' for Avid, says RBC Capital
03/16/21 RBC Capital
RBC starts Avid Bioservices at Outperform with $21 price target
03/16/21 RBC Capital
Avid Bioservices initiated with an Outperform at RBC Capital
02/01/21 KeyBanc
Avid Bioservices price target raised to $22 from $12 at KeyBanc
ADCT ADC Therapeutics
$20.91 /

+0.06 (+0.29%)

05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
12/02/20 Stifel
ADC Therapeutics initiated with a Hold at Stifel
CDMO Avid Bioservices
$20.17 /

+0.1 (+0.50%)

ADCT ADC Therapeutics
$20.91 /

+0.06 (+0.29%)

  • 10
    Dec
  • 24
    Sep
CDMO Avid Bioservices
$20.17 /

+0.1 (+0.50%)

Over a month ago
Hot Stocks
ADC Therapeutics announces three abstracts to be presented at ASCO » 18:46
05/19/21
05/19
18:46
05/19/21
18:46
ADCT

ADC Therapeutics

$20.33 /

-0.61 (-2.91%)

ADC Therapeutics…

ADC Therapeutics announced three abstracts have been selected for poster presentations at the 2021 American Society of Clinical Oncology Annual Meeting, which is being held virtually June 4-8, 2021. Posters will "highlight ZYNLONTA(TM) LOTIS-2 subgroup analyses, ZYNLONTA(TM) LOTIS-5 confirmatory trial and Cami in advanced solid tumors", the company states.

ShowHide Related Items >><<
ADCT ADC Therapeutics
$20.33 /

-0.61 (-2.91%)

ADCT ADC Therapeutics
$20.33 /

-0.61 (-2.91%)

05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
12/02/20 Stifel
ADC Therapeutics initiated with a Hold at Stifel
ADCT ADC Therapeutics
$20.33 /

-0.61 (-2.91%)

  • 24
    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.